Trial Profile
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2023
Price :
$35
*
At a glance
- Drugs GSK 2831781 (Primary) ; GSK 2831781 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 16 Jun 2023 Results published in the Alimentary Pharmacology and Therapeutics
- 16 Feb 2021 Planned End Date changed from 19 May 2023 to 6 May 2021.
- 16 Feb 2021 Planned primary completion date changed from 13 Jul 2022 to 6 May 2021.